Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Egle Therapeutics

Request full access

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically…

Paris, FranceFounded 2020Biotech & Life Sciences

About Egle Therapeutics

Egle Therapeutics is a biotech startup that specializes in developing innovative immunotherapies. The company's primary focus is on targeting suppressor regulatory T cells (Tregs), which play a crucial role in the immune system. These cells are particularly relevant in the treatment of cancer and autoimmune diseases, where the immune response is often compromised.

Founded in 2020, Egle Therapeutics was established by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, Director of the Translational Immunotherapy Team at Institut Curie. The company's approach combines the use of antibody-specific targeting with modified cytokine, a type of small protein important in cell signaling, to either enhance or suppress the most immunosuppressive Tregs. This unique method aims to restore the immune response, offering potential breakthroughs in the treatment of severe diseases.

Egle Therapeutics operates in the biotech market, serving clients in the medical and healthcare sectors. The company's business model is centered around the development and commercialization of its first-in-class immunotherapies. The company generates revenue through the development of its drug pipeline, which includes novel immunotherapies against Tregs.

The company's name, Egle, is inspired by the Greek myth of Aglaea, symbolizing beauty, splendor, glory, and magnificence. This reflects the company's mission to bring hope to patients suffering from severe diseases and to deploy remarkable science to meet unmet medical needs.

Source: Dealroom company data

At a glance

Status
Operational
Employees
52
Open positions
None listed
Dealroom signal
80.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Woman Founder, participations bpifrance, radar de l'innovation, observatoire industrial tech, proteomics
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Mar 2025 $10M — France 2030 ↗
SERIES AOther financing Oct 2021 $44M $176M Takeda · FundPlus · Bioqube Ventures · Bpifrance —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Egle Therapeutics website traffic

Latest recorded traffic for Egle Therapeutics is 1.5K monthly website visits, down 50% over the last three months. Egle Therapeutics's team grew 6.1% over the past year.

Latest monthly visits1.5K 3-month web change-50% 1-year team growth+6.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Egle Therapeutics in the Paris ecosystem

Live from Dealroom

The Egle Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • France 2030

Series A6 investors entered at this stage

  • Bpifrance
  • EQT Life Sciences
  • InnoBio 2
  • Takeda
  • FundPlus
  • Bioqube Ventures

Other known investors4 additional known investors

  • CNRS Innovation
  • French National Centre for Scientific Research - CNRS
  • Institut Curie
  • PSL University
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
7 countries with
team presence
🇫🇷 France75.7%
🇺🇸 United States8.1%
🇧🇪 Belgium5.4%
🇨🇭 Switzerland2.7%
🇳🇱 Netherlands2.7%
Top 5 of 7 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Egle Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Egle Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.